Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
P49810
UPID:
PSN2_HUMAN
Alternative names:
AD3LP; AD5; E5-1; STM-2
Alternative UPACC:
P49810; A8K8D4; B1AP21; Q96P32
Background:
Presenilin-2, known by alternative names such as AD3LP, AD5, E5-1, and STM-2, plays a crucial role in the gamma-secretase complex, essential for the intramembrane cleavage of proteins like Notch receptors and APP. This protein is pivotal in cellular signaling, gene expression, and the regulation of calcium homeostasis, facilitating calcium movement from the endoplasmic reticulum to the cytosol.
Therapeutic significance:
Presenilin-2's involvement in Alzheimer disease 4 and Cardiomyopathy, dilated, 1V, underscores its potential as a target for therapeutic intervention. Understanding the role of Presenilin-2 could open doors to potential therapeutic strategies, particularly in neurodegenerative disorders and heart diseases.